Analysts See $-0.28 EPS for Intec Pharma Ltd. (NTEC) on June, 8

May 17, 2018 - By Yee Bell

Intec Pharma Ltd. (NASDAQ:NTEC) Corporate Logo

On June, 8 WallStreet anticipated Intec Pharma Ltd. (NASDAQ:NTEC)’s earnings release, according to RTT. Analysts at Wall Street see Intec Pharma Ltd.’s -28.21 % EPS growth compared to $-0.39 EPS for previous quarter. $4.85 was the last price.It’s uptrending since May 17, 2017 and is 25.00% up. The stock outperformed the S&P500 by 13.45%.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel.The company has $164.22 million market cap. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.Last it reported negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

Intec Pharma Ltd. (NASDAQ:NTEC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.